About EYLEA Results of phase 3 trials are presented for EYLEA.1 See the data
EYLEA (aflibercept) Injection vial and packaging

Proven Results Across All Approved Indications

EYLEA indications are backed by 7 pivotal studies evaluating BCVA as measured by ETDRS* letters in over 3000 patients: VIEW 1 and VIEW 2 (Wet AMD) at 52 weeks, VISTA and VIVID (DME and DR in Patients with DME) at 52 and 100 weeks, GALILEO and COPERNICUS (MEfCRVO) at 24 weeks, and VIBRANT (MEfBRVO) at 24 weeks.1 When starting a patient on EYLEA, consider the body of evidence demonstrating proven results.1

See outcomes

Accessing EYLEA Comprehensive support for you and your patients. Find support
Patient Support

We're committed to help ensure your eligible patients have access to EYLEA, regardless of insurance or coverage. 

Reimbursement

Get help navigating the reimbursement process. Find enrollment forms, sample appeal letters, and more. 

Product Support

Find complete product support—guiding you through orders, returns, and more. 

News Stay informed on current EYLEA clinical information, events, and more. Read the latest
5 Oct
Explore EYLEA at AAO

Look for Regeneron booth 4239 at AAO in New Orleans November 11-14. Stop by, make eye contact with us, and discover more about EYLEA. 

11 Nov
Experience What Certain Retinal Diseases Can Be Like In Virtual Reality

Discover In My Eyes, a unique app that lets patients and caregivers experience retinal disease symptoms firsthand in 360° virtual and augmented reality. 

  • * Best Corrected Visual Acuity as measured by Early Treatment Diabetic Retinopathy Study
  • anti-VEGF = anti–Vascular Endothelial Growth Factor
  • AMD = Age-related Macular Degeneration
  • MEfRVO = Macular Edema following Retinal Vein Occlusion (includes Branch Retinal Vein Occlusion [BRVO] and Central Retinal Vein Occlusion [CRVO])
  • DME = Diabetic Macular Edema
  • DR = Diabetic Retinopathy
Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information Important Prescribing Information

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. May 2017.